↓ Skip to main content

Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in Escherichia coli and protection potency evaluation in cattle

Overview of attention for article published in BMC Biotechnology, July 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
89 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in Escherichia coli and protection potency evaluation in cattle
Published in
BMC Biotechnology, July 2016
DOI 10.1186/s12896-016-0285-6
Pubmed ID
Authors

Yan Xiao, Hong-Ying Chen, Yuzhou Wang, Bo Yin, Chaochao Lv, Xiaobing Mo, He Yan, Yajie Xuan, Yuxin Huang, Wenqiang Pang, Xiangdong Li, Y. Adam Yuan, Kegong Tian

Abstract

Foot-and-mouth disease (FMD) is an acute, highly contagious disease that infects cloven-hoofed animals. Vaccination is an effective means of preventing and controlling FMD. Compared to conventional inactivated FMDV vaccines, the format of FMDV virus-like particles (VLPs) as a non-replicating particulate vaccine candidate is a promising alternative. In this study, we have developed a co-expression system in E. coli, which drove the expression of FMDV capsid proteins (VP0, VP1, and VP3) in tandem by a single plasmid. The co-expressed FMDV capsid proteins (VP0, VP1, and VP3) were produced in large scale by fermentation at 10 L scale and the chromatographic purified capsid proteins were auto-assembled as VLPs in vitro. Cattle vaccinated with a single dose of the subunit vaccine, comprising in vitro assembled FMDV VLP and adjuvant, developed FMDV-specific antibody response (ELISA antibodies and neutralizing antibodies) with the persistent period of 6 months. Moreover, cattle vaccinated with the subunit vaccine showed the high protection potency with the 50 % bovine protective dose (PD50) reaching 11.75 PD50 per dose. Our data strongly suggest that in vitro assembled recombinant FMDV VLPs produced from E. coli could function as a potent FMDV vaccine candidate against FMDV Asia1 infection. Furthermore, the robust protein expression and purification approaches described here could lead to the development of industrial level large-scale production of E. coli-based VLPs against FMDV infections with different serotypes.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 1%
Sweden 1 1%
Unknown 87 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 21%
Student > Master 13 15%
Student > Ph. D. Student 10 11%
Student > Bachelor 9 10%
Student > Postgraduate 5 6%
Other 10 11%
Unknown 23 26%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 23 26%
Agricultural and Biological Sciences 19 21%
Veterinary Science and Veterinary Medicine 12 13%
Immunology and Microbiology 3 3%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 6 7%
Unknown 24 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2021.
All research outputs
#6,979,392
of 22,880,230 outputs
Outputs from BMC Biotechnology
#388
of 935 outputs
Outputs of similar age
#114,213
of 350,781 outputs
Outputs of similar age from BMC Biotechnology
#6
of 14 outputs
Altmetric has tracked 22,880,230 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 935 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,781 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.